answering body |
Department of Health and Social Care |
|
|
question text |
To ask His Majesty's Government, further to the Written Answer by Lord Markham on
6 March (HL5937), why the National Institute for Clinical Excellence (NICE) request
for referral of 8 June is described as for “referral of Evusheld for treatment of
COVID-19” but, as confirmed in a NICE freedom of information response, the request
was for “referral of tixagevimab-cilgavimab for preventing COVID-19 [ID6136] on 8
June 2022”, causing delay to the possibility of a decision at a time when the preventative
prophylaxis Evusheld was highly efficacious.
|
|